Corbus Pharmaceuticals Holdings, Inc. announced that it has received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Development Award enables the company to execute its Phase 2b study of its novel, oral, pro-resolving drug lenabasum (formerly known as anabasum) in approximately 415 people with cystic fibrosis ("CF") who are 12 years and older and at increased risk for pulmonary exacerbations.